Measuring the success of blinding in placebo-controlled trials: Should we be so quick to dismiss it?
journal contributionposted on 2021-10-15, 08:55 authored by Rebecca K Webster, Felicity Bishop, Gary S Collins, Andrea WM Evers, Tammy Hoffmann, J André Knottnerus, Sarah E Lamb, Helen Macdonald, Claire MadiganClaire Madigan, Vitaly Napadow, Amy Price, Jonathan L Rees, Jeremy Howick
‘Blinding’ involves concealing knowledge of which trial participants received the interventions from participants themselves and other trial personnel throughout the trial. Blinding reduces bias arising from the beliefs and expectations of these groups. It is agreed that where possible, blinding should be attempted, for example by ensuring that experimental and control treatments look the same. However, there is a debate about if we should measure whether blinding has been successful, this manuscript will discuss this controversy, including the benefits and risks of measuring blinding within the randomised controlled trial.
University of Oxford Humanities Division REF Support Fund
Netherlands Organization for Scientific Research (NWO) (Number: 45316004)
European Research Council Consolidator Grant (ERC2013-CoG-617700)
National Institutes of Health, National Center for Complementary and Integrative Health (R01- AT007550, R61/R33-AT009306, P01- AT009965)
National Institute of 16 Arthritis and Musculoskeletal and Skin Diseases (R01- AR064367)
NIHR Biomedical Research Centre, Oxford and Cancer Research UK (grant C49297/A27294)
National Health and Medical Research Council of Australia Senior Research Fellowship
- Sport, Exercise and Health Sciences